BioMed Central | Articles which cite: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.

Log on / register
Feedback | Support | My details

home journals A-Z subject areas advanced search authors reviewers libraries about my BioMed Central

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J
Arthritis Res Ther 2005, 7:R439-44
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]

printer friendly

to [Help]

PubMed Central articles that cite the above article:

1.	TNFalpha blockade in human diseases: an overview of efficacy and safety. Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, Braun J, Reed E, Gjertson D, Singh RR Clin Immunol 2008 Jan, 126:13-30 [PubMed Central] [PubMed] [Related articles]
2.	First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D, ASAS Working Group Ann Rheum Dis 2006 Mar, 65:316-20 [PubMed Central] [PubMed] [Related articles]
3.	Infliximab in the treatment of ankylosing spondylitis. Grainger R, Harrison AA Biologics 2007 Jun, 1:163-71 [PubMed Central] [PubMed] [Related articles]
4.	Tumor necrosis factor-alpha blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification? Van den Bosch F, De Keyser F, Mielants H, Veys EM Arthritis Res Ther 2005, 7:121-3 [PubMed Central] [PubMed] [Related articles]
5.	How early should ankylosing spondylitis be treated with tumour necrosis factor blockers? Sieper J, Rudwaleit M Ann Rheum Dis 2005 Nov, 64 Suppl 4:iv61-4 [PubMed Central] [PubMed] [Related articles]
6.	Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ Ann Rheum Dis 2005 Nov, 64 Suppl 4:iv2-14 [PubMed Central] [PubMed] [Related articles]

This article is also cited by 3 articles in BioMed Central

You can also check ISI Web of Science for additional citations (subscription required)

printer friendly

to [Help]

Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us